Our anti-SFXN4 in ovarian cancer therapy
January 2023 (Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, CT, 06030, USA)
Sideroflexin 4 is overexpressed in ovarian cancer tissue and ovarian cancer cell lines.
Tesfay, L., Paul, B.T., Hegde, P. et al. Complementary anti-cancer pathways triggered by inhibition of sideroflexin 4 in ovarian cancer. Sci Rep 12, 19936 (2022).
An excellent paper published in Nature - Scientific Reports investigating Sideroflexin 4 (SFXN4) as a new target in ovarian cancer therapy.
Ovarian cancer comprises multiple histological subtypes. The most prevalent are surface epithelial cancers, including high-grade serous ovarian cancer (HGSOC), the most common and lethal subtype, as well as endometrioid and other less common histological subtypes.
To explore expression levels of SFXN4 in human ovarian cancer, authors performed IHC staining of SFXN4 in tissue obtained from ovarian cancer patients.
Immunohistochemical staining using our anti-SFXN4 (HPA020872) polyclonal antibody demonstrated a striking and statistically significant increase in SFXN4 expression in both HGSOC and endometrioid tumor tissue when compared to normal ovarian surface epithelium and fimbriae of the fallopian tube, tissues of origin of these cancers.
Read the full article here.
🌏 Our antibodies are used worldwide!
Read more about our antibodies in action 🌏
Interested in antibodies targeting ovarian cancer? Check out the infographic!